Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome.

Autor: Iihara, Hirotoshi, Fujii, Hironori, Yoshimi, Chiaki, Kobayashi, Ryo, Matsuhashi, Nobuhisa, Takahashi, Takao, Yoshida, Kazuhiro, Suzuki, Akio
Předmět:
Zdroj: Cancer Chemotherapy & Pharmacology; Mar2019, Vol. 83 Issue 3, p393-398, 6p
Abstrakt: Background/aim: Cholinergic syndrome frequently occurs within the first 24 h after irinotecan injection. We evaluated the prophylactic effect of scopolamine butylbromide on irinotecan-related cholinergic syndrome.Patients and Methods: Fifty-nine patients who received irinotecan-based regimens at our outpatient chemotherapy clinic between April 2013 and May 2014 were enrolled. Patients who developed irinotecan-related cholinergic syndrome were prophylactically administered scopolamine butylbromide at the next scheduled treatment. Risk factors for irinotecan-related cholinergic syndrome were determined using logistic regression analysis.Results: Irinotecan-related cholinergic syndrome occurred in 50.8% of patients. Scopolamine butylbromide administration significantly reduced the incidence to 3.4% (P < 0.01). The irinotecan dose (≥ 150 mg/m2) was the only risk factor associated with irinotecan-related cholinergic syndrome. The incidence of cholinergic syndrome in patients with this risk factor was 75%.Conclusion: Scopolamine butylbromide was effective in preventing irinotecan-related cholinergic syndrome. It is recommended for patients receiving ≥ 150 mg/m2 irinotecan who may develop cholinergic syndrome at high frequency. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: